Logo image of RXRX

RECURSION PHARMACEUTICALS-A (RXRX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RXRX - US75629V1044 - Common Stock

4.41 USD
+0.04 (+0.92%)
Last: 11/26/2025, 8:02:28 PM
4.43 USD
+0.02 (+0.45%)
After Hours: 11/26/2025, 8:02:28 PM
Fundamental Rating

2

Taking everything into account, RXRX scores 2 out of 10 in our fundamental rating. RXRX was compared to 533 industry peers in the Biotechnology industry. RXRX may be in some trouble as it scores bad on both profitability and health. RXRX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RXRX had negative earnings in the past year.
RXRX had a negative operating cash flow in the past year.
In the past 5 years RXRX always reported negative net income.
RXRX had a negative operating cash flow in each of the past 5 years.
RXRX Yearly Net Income VS EBIT VS OCF VS FCFRXRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

RXRX has a Return On Assets (-51.13%) which is comparable to the rest of the industry.
The Return On Equity of RXRX (-68.35%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -51.13%
ROE -68.35%
ROIC N/A
ROA(3y)-38.78%
ROA(5y)-35.21%
ROE(3y)-54.96%
ROE(5y)-47.04%
ROIC(3y)N/A
ROIC(5y)N/A
RXRX Yearly ROA, ROE, ROICRXRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

RXRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RXRX Yearly Profit, Operating, Gross MarginsRXRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

3

2. Health

2.1 Basic Checks

RXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RXRX has more shares outstanding
The number of shares outstanding for RXRX has been increased compared to 5 years ago.
RXRX has a worse debt/assets ratio than last year.
RXRX Yearly Shares OutstandingRXRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M
RXRX Yearly Total Debt VS Total AssetsRXRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

Based on the Altman-Z score of 0.06, we must say that RXRX is in the distress zone and has some risk of bankruptcy.
RXRX's Altman-Z score of 0.06 is fine compared to the rest of the industry. RXRX outperforms 61.35% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that RXRX is not too dependend on debt financing.
RXRX has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: RXRX outperforms 44.65% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 0.06
ROIC/WACCN/A
WACC8.62%
RXRX Yearly LT Debt VS Equity VS FCFRXRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 4.60 indicates that RXRX has no problem at all paying its short term obligations.
The Current ratio of RXRX (4.60) is comparable to the rest of the industry.
RXRX has a Quick Ratio of 4.60. This indicates that RXRX is financially healthy and has no problem in meeting its short term obligations.
RXRX's Quick ratio of 4.60 is in line compared to the rest of the industry. RXRX outperforms 54.41% of its industry peers.
Industry RankSector Rank
Current Ratio 4.6
Quick Ratio 4.6
RXRX Yearly Current Assets VS Current LiabilitesRXRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

RXRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.13%.
RXRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -32.98%.
RXRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 90.91% yearly.
EPS 1Y (TTM)-16.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.88%
Revenue 1Y (TTM)-32.98%
Revenue growth 3Y79.46%
Revenue growth 5Y90.91%
Sales Q2Q%-80.16%

3.2 Future

The Earnings Per Share is expected to grow by 7.30% on average over the next years.
RXRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.46% yearly.
EPS Next Y1.46%
EPS Next 2Y11.41%
EPS Next 3Y12.79%
EPS Next 5Y7.3%
Revenue Next Year1.25%
Revenue Next 2Y10.67%
Revenue Next 3Y39.31%
Revenue Next 5Y28.46%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RXRX Yearly Revenue VS EstimatesRXRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
RXRX Yearly EPS VS EstimatesRXRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RXRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RXRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXRX Price Earnings VS Forward Price EarningsRXRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RXRX Per share dataRXRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as RXRX's earnings are expected to grow with 12.79% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.41%
EPS Next 3Y12.79%

More info and screens

0

5. Dividend

5.1 Amount

RXRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RECURSION PHARMACEUTICALS-A

NASDAQ:RXRX (11/26/2025, 8:02:28 PM)

After market: 4.43 +0.02 (+0.45%)

4.41

+0.04 (+0.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)02-26 2026-02-26/bmo
Inst Owners69.36%
Inst Owner Change5.89%
Ins Owners2.56%
Ins Owner Change-0.14%
Market Cap1.91B
Revenue(TTM)43.69M
Net Income(TTM)-715.54M
Analysts72.86
Price Target6.46 (46.49%)
Short Float %31.59%
Short Ratio2.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.12%
Min EPS beat(2)-14.85%
Max EPS beat(2)4.61%
EPS beat(4)2
Avg EPS beat(4)-5.99%
Min EPS beat(4)-20.37%
Max EPS beat(4)6.63%
EPS beat(8)6
Avg EPS beat(8)0.03%
EPS beat(12)8
Avg EPS beat(12)-0.78%
EPS beat(16)10
Avg EPS beat(16)-27.82%
Revenue beat(2)1
Avg Revenue beat(2)-24.01%
Min Revenue beat(2)-70.13%
Max Revenue beat(2)22.11%
Revenue beat(4)1
Avg Revenue beat(4)-36.25%
Min Revenue beat(4)-76.78%
Max Revenue beat(4)22.11%
Revenue beat(8)3
Avg Revenue beat(8)-24.17%
Revenue beat(12)3
Avg Revenue beat(12)-23.68%
Revenue beat(16)5
Avg Revenue beat(16)-19.55%
PT rev (1m)-2.06%
PT rev (3m)-2.06%
EPS NQ rev (1m)-1.49%
EPS NQ rev (3m)-0.49%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.78%
Revenue NQ rev (1m)11.18%
Revenue NQ rev (3m)11.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 43.82
P/FCF N/A
P/OCF N/A
P/B 1.83
P/tB 3.4
EV/EBITDA N/A
EPS(TTM)-1.8
EYN/A
EPS(NY)-1.26
Fwd EYN/A
FCF(TTM)-1.03
FCFYN/A
OCF(TTM)-1.02
OCFYN/A
SpS0.1
BVpS2.41
TBVpS1.3
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -51.13%
ROE -68.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.78%
ROA(5y)-35.21%
ROE(3y)-54.96%
ROE(5y)-47.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.45%
Cap/Sales 14.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.6
Quick Ratio 4.6
Altman-Z 0.06
F-Score4
WACC8.62%
ROIC/WACCN/A
Cap/Depr(3y)133.89%
Cap/Depr(5y)201.24%
Cap/Sales(3y)47.71%
Cap/Sales(5y)136.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.88%
EPS Next Y1.46%
EPS Next 2Y11.41%
EPS Next 3Y12.79%
EPS Next 5Y7.3%
Revenue 1Y (TTM)-32.98%
Revenue growth 3Y79.46%
Revenue growth 5Y90.91%
Sales Q2Q%-80.16%
Revenue Next Year1.25%
Revenue Next 2Y10.67%
Revenue Next 3Y39.31%
Revenue Next 5Y28.46%
EBIT growth 1Y-84.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-54.69%
EBIT Next 3Y-3.35%
EBIT Next 5YN/A
FCF growth 1Y-62.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70.7%
OCF growth 3YN/A
OCF growth 5YN/A

RECURSION PHARMACEUTICALS-A / RXRX FAQ

What is the ChartMill fundamental rating of RECURSION PHARMACEUTICALS-A (RXRX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to RXRX.


Can you provide the valuation status for RECURSION PHARMACEUTICALS-A?

ChartMill assigns a valuation rating of 0 / 10 to RECURSION PHARMACEUTICALS-A (RXRX). This can be considered as Overvalued.


Can you provide the profitability details for RECURSION PHARMACEUTICALS-A?

RECURSION PHARMACEUTICALS-A (RXRX) has a profitability rating of 1 / 10.